0001598308 false 6/30 2021 Q2 0001598308 2021-07-01 2021-12-31 0001598308 2022-01-13 0001598308 2021-12-31 0001598308 2021-06-30 0001598308 2021-10-01 2021-12-31 0001598308 2020-10-01 2020-12-31 0001598308 2020-07-01 2020-12-31 0001598308 us-gaap:CommonStockMember 2021-06-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001598308 gwhp:CommonStockPayableMember 2021-06-30 0001598308 gwhp:DeferredCompenstionMember 2021-06-30 0001598308 us-gaap:RetainedEarningsMember 2021-06-30 0001598308 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001598308 gwhp:CommonStockPayableMember 2021-07-01 2021-09-30 0001598308 gwhp:DeferredCompenstionMember 2021-07-01 2021-09-30 0001598308 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001598308 2021-07-01 2021-09-30 0001598308 us-gaap:CommonStockMember 2021-09-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001598308 gwhp:CommonStockPayableMember 2021-09-30 0001598308 gwhp:DeferredCompenstionMember 2021-09-30 0001598308 us-gaap:RetainedEarningsMember 2021-09-30 0001598308 2021-09-30 0001598308 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001598308 gwhp:CommonStockPayableMember 2021-10-01 2021-12-31 0001598308 gwhp:DeferredCompenstionMember 2021-10-01 2021-12-31 0001598308 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001598308 us-gaap:CommonStockMember 2021-12-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001598308 gwhp:CommonStockPayableMember 2021-12-31 0001598308 gwhp:DeferredCompenstionMember 2021-12-31 0001598308 us-gaap:RetainedEarningsMember 2021-12-31 0001598308 us-gaap:CommonStockMember 2020-06-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001598308 gwhp:CommonStockPayableMember 2020-06-30 0001598308 gwhp:DeferredCompenstionMember 2020-06-30 0001598308 us-gaap:RetainedEarningsMember 2020-06-30 0001598308 2020-06-30 0001598308 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001598308 gwhp:CommonStockPayableMember 2020-07-01 2020-09-30 0001598308 gwhp:DeferredCompenstionMember 2020-07-01 2020-09-30 0001598308 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001598308 2020-07-01 2020-09-30 0001598308 us-gaap:CommonStockMember 2020-09-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001598308 gwhp:CommonStockPayableMember 2020-09-30 0001598308 gwhp:DeferredCompenstionMember 2020-09-30 0001598308 us-gaap:RetainedEarningsMember 2020-09-30 0001598308 2020-09-30 0001598308 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001598308 gwhp:CommonStockPayableMember 2020-10-01 2020-12-31 0001598308 gwhp:DeferredCompenstionMember 2020-10-01 2020-12-31 0001598308 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001598308 us-gaap:CommonStockMember 2020-12-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001598308 gwhp:CommonStockPayableMember 2020-12-31 0001598308 gwhp:DeferredCompenstionMember 2020-12-31 0001598308 us-gaap:RetainedEarningsMember 2020-12-31 0001598308 2020-12-31 0001598308 gwhp:CommonStocksMember gwhp:EmpireAssociatesIncMember 2021-04-19 2021-04-20 0001598308 us-gaap:RestrictedStockMember gwhp:MediaAndMarketingServicesAgreementMember 2021-07-01 2021-07-10 0001598308 us-gaap:RestrictedStockMember gwhp:MediaAndMarketingServicesAgreementMember 2021-07-10 0001598308 gwhp:CommonStockPurchaseAgreementMember 2020-07-21 2020-07-22 0001598308 srt:MinimumMember 2021-10-01 2021-12-31 0001598308 srt:MaximumMember 2021-10-01 2021-12-31 0001598308 srt:MinimumMember 2021-07-01 2021-12-31 0001598308 srt:MaximumMember 2021-07-01 2021-12-31 0001598308 gwhp:WarrantsMember gwhp:EMC2CapitalMember 2021-07-01 2021-12-31 0001598308 gwhp:WarrantsMember gwhp:EMC2CapitalMember 2020-07-01 2021-06-30 0001598308 gwhp:WarrantsMember gwhp:GenevaMember 2021-07-01 2021-12-31 0001598308 gwhp:WarrantsMember gwhp:GenevaMember 2020-07-01 2021-06-30 0001598308 gwhp:WarrantsOneMember gwhp:FirstfireMember 2021-07-01 2021-12-31 0001598308 gwhp:WarrantsOneMember gwhp:FirstfireMember 2020-07-01 2021-06-30 0001598308 gwhp:WarrantsTwoMember gwhp:FirstfireMember 2021-07-01 2021-12-31 0001598308 gwhp:WarrantsTwoMember gwhp:FirstfireMember 2020-07-01 2021-06-30 0001598308 2020-07-01 2021-06-30 0001598308 gwhp:LionsGateMember 2021-07-02 0001598308 gwhp:PanProbeMember 2021-10-01 2021-12-31 0001598308 gwhp:PanProbeMember 2020-10-01 2020-12-31 0001598308 gwhp:PanProbeMember 2021-07-01 2021-12-31 0001598308 gwhp:PanProbeMember 2020-07-01 2020-12-31 0001598308 gwhp:PanProbeMember 2021-12-31 0001598308 gwhp:PanProbeMember 2021-06-30 0001598308 gwhp:PanProbeMember 2020-04-30 0001598308 gwhp:LionsGateFundingGroupLLCMember us-gaap:NotesPayableOtherPayablesMember 2020-06-30 0001598308 gwhp:LionsGateFundingGroupLLCMember us-gaap:NotesPayableOtherPayablesMember 2021-02-21 0001598308 gwhp:LionsGeteMember 2021-10-01 2021-12-31 0001598308 gwhp:LionsGeteMember 2020-10-01 2020-12-31 0001598308 gwhp:LionsGeteMember 2021-07-01 2021-12-31 0001598308 gwhp:LionsGeteMember 2020-07-01 2020-12-31 0001598308 gwhp:LionsGateMember 2021-07-01 2021-12-31 0001598308 us-gaap:RestrictedStockMember gwhp:FiveSeparateUnsecuredConvertiblePromissoryNotesMember 2020-04-17 2020-04-18 0001598308 us-gaap:RestrictedStockMember gwhp:FiveSeparateUnsecuredConvertiblePromissoryNotesMember 2020-04-18 0001598308 us-gaap:RestrictedStockMember gwhp:FiveSeparateUnsecuredConvertiblePromissoryNotesMember 2020-12-31 0001598308 2021-11-30 0001598308 gwhp:FirstfireGlobalOpportunitiesFundLlcMember gwhp:SeniorSecuredConvertiblePromissoryNotesMember 2021-06-18 0001598308 gwhp:FirstfireWarrantMember 2021-06-17 2021-06-18 0001598308 gwhp:FirstfireGlobalOpportunitiesFundLlcMember gwhp:SeniorSecuredConvertiblePromissoryNotesMember 2021-07-02 2021-07-08 0001598308 gwhp:FirstfireGlobalOpportunitiesFundLlcMember gwhp:SeniorSecuredConvertiblePromissoryNotesMember 2021-07-08 0001598308 2021-06-18 0001598308 us-gaap:RestrictedStockMember 2020-12-15 0001598308 gwhp:FirstfireWarrantMember 2021-06-18 0001598308 gwhp:SeniorSecuredConvertiblePromissoryNoteMember 2021-07-02 2021-07-08 0001598308 gwhp:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-07-01 2021-12-31 0001598308 gwhp:WarrantsMember gwhp:FirstfireNoteNoTwoMember 2021-08-01 2021-08-27 0001598308 gwhp:FirstfireNoteNoTwoMember 2021-08-01 2021-08-27 0001598308 gwhp:FirstfireNoteNoTwoMember 2021-08-27 0001598308 gwhp:WarrantsMember gwhp:FirstfireNoteNoTwoMember 2021-08-27 0001598308 gwhp:WarrantsMember gwhp:FirstfireNoteNoTwoMember 2021-12-31 0001598308 gwhp:FirstfireNoteNoTwoMember 2021-07-01 2021-12-31 0001598308 gwhp:SecuritiesPurchaseAgreementMember gwhp:GenevaPromissoryNoteMember 2021-04-26 0001598308 gwhp:SecuritiesPurchaseAgreementMember gwhp:GenevaPromissoryNoteMember 2021-04-01 2021-04-26 0001598308 gwhp:GenevaPromissoryNoteMember 2021-08-01 2021-08-09 0001598308 gwhp:WarrantsMember gwhp:FirstfireNoteNoTwoMember 2021-07-01 2021-12-31 0001598308 gwhp:ConvertibleNotePayableDatedJulyThirteenTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2020-07-13 0001598308 gwhp:ConvertibleNotePayableDatedAugustThreeTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2020-08-03 0001598308 gwhp:ConvertibleNotePayableDatedSeptemberEightTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2020-09-08 0001598308 gwhp:ConvertibleNotePayableDatedJulyThirteenTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2020-07-12 2020-07-13 0001598308 gwhp:ConvertibleNotePayableDatedAugustThreeTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2020-08-02 2020-08-03 0001598308 gwhp:ConvertibleNotePayableDatedSeptemberEightTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2020-09-07 2020-09-08 0001598308 gwhp:ConvertibleNotePayableDatedJulyThirteenTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2020-12-20 2020-12-21 0001598308 gwhp:ConvertibleNotePayableDatedSeptemberEightTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2021-02-15 2021-02-16 0001598308 gwhp:ConvertibleNotePayableDatedSeptemberEightTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2021-02-16 0001598308 gwhp:WarrantsMember gwhp:FirstfireNoteNoTwoMember 2021-03-15 0001598308 gwhp:ConvertibleNotePayableDatedSeptemberEightTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2021-03-15 0001598308 gwhp:ConvertibleNotePayableDatedSeptemberEightTwoThousandTwentyMember gwhp:SeparateAndIdenticalSecuritiesPurchaseAgreementsMember 2021-03-14 2021-03-15 0001598308 gwhp:FiveSeparateUnsecuredConvertiblePromissoryNotesMember 2020-10-01 2020-12-31 0001598308 gwhp:FiveSeparateUnsecuredConvertiblePromissoryNotesMember 2020-07-01 2020-12-31 0001598308 2021-09-01 2021-09-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~December~~March 31, ~~2021~~2022

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission file number 000-56035

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

(Exact name of registrant as specified in its charter)

Nevada		46-2316220
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1130 Calle Cordillera
San Clemente, California		92673
(Address of principal executive offices)		(Zip Code)

(714) 392-9752

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act). Yes ☐ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 87107,~~984~~587,~~670~~079 shares of common stock, par value $0.001, were outstanding on ~~January~~July 1320, 2022.

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

FORM 10-Q

For the Quarterly Period Ended ~~December~~March 31, ~~2021~~2022

Table of Contents

PART I.	FINANCIAL INFORMATION
	Item 1.	Financial Statements (Unaudited)	4
		Balance Sheets	4
		Statements of Operations	5
		Statements of Stockholders’ Equity	6
		Statements of Cash Flows	7
		Notes to Financial Statements	8
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
	Item 4.	Controls and Procedures	22
PART II.	OTHER INFORMATION
	Item 1A.	Risk Factors	23
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
	Item 6.	Exhibits	24
	Signatures		26
	Certifications

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
CONSOLIDATED BALANCE SHEETS

	December 31,			June 30,
	March 31,			June 30,
	2021			2021
	2022			2021
ASSETS	(Unaudited)
Current assets:
Cash	$	6127,~~693~~416		$	74,702
Prepaid expenses and other current assets		~~156~~111,~~380~~226			27,918
Inventory, net		9386,~~681~~000			29,681
Deferred financing costs		—			271,814
Total current assets		~~311~~224,~~754~~642			404,115
Operating lease right-of-use asset		~~498~~476,~~672~~125			—
Equipment, net of accumulated depreciation of $1,648 and $1,067		1,856			2,438
Equipment, net of accumulated depreciation of $1,939 and $1,067		1,565			2,438
Investment in related party common stock		5,000			5,000
Deposits		32,621			—
Total assets	$	~~849~~739,~~903~~953		$	411,553
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Related party note	$	—		$	2,785
Convertible notes payable, net of discount of $0 and $27,460, respectively		~~886~~806,400			85,000
Notes payable		—			43,320
Accounts payable and accrued liabilities		~~366~~362,~~616~~357			148,946
Related party payables		~~597~~638,~~577~~827			225,598
Lease liabilities, current		8688,~~009~~348			—
Total current liabilities		1,~~936~~895,~~602~~932			508,649
Lease liabilities, non-current		~~414~~391,~~462~~375
Total liabilities		2,~~351~~287,~~064~~307			508,649
Commitments and contingencies
Stockholders' equity (deficit):
Common stock; $0.001 par value, 400,000,000 shares authorized, 87,984,670 and 78,713,899 shares issued and outstanding at December 31, 2021 and June 30, 2021, respectively		87,984			78,714
Common stock; $0.001 par value, 400,000,000 shares authorized, 107,587,079 and 78,713,899 shares issued and outstanding at March 31, 2022 and June 30, 2021, respectively		107,486			78,714
Additional paid-in capital		1617,~~309~~136,~~138~~506			13,529,861
Common stock payable		—8,700			77,061
Deferred compensation		(6432,~~500~~250	)		—
Retained deficit		(1718,~~833~~767,~~783~~796	)		(13,782,732	)
Total stockholders' equity (deficit)		(1,~~501~~547,~~161~~354	)		(97,096	)
Total liabilities and stockholders' equity (deficit)	$	~~849~~739,~~903~~953		$	411,553
(The accompanying notes are an integral part of these consolidated financial statements)

(The accompanying notes are an integral part of these consolidated financial statements)

GLOBAL WHOLEHEALTH PARTNERS CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

		Three Months Ended March 31,						Nine Months Ended March 31,
		2022			2021			2022			2021
Revenue	$	7,000		$	2,460		$	7,375		$	39,920
Cost of revenue		33,681			54,540			33,681			82,671
Gross profit		(26,681	)		(52,080	)		(26,306	)		(42,751	)

Operating expenses
Professional fees		32,132			14,400			103,532			61,625
Research and development - related party		—			20,000			1,369,097			213,310
Research and development		3,000			10,000			3,600			20,700
Selling, general and administrative - related party		659,250			2,544,000			773,750			2,582,381
Selling, general and administrative		212,260			22,980			1,741,622			39,260
Total operating expense		906,642			2,611,380			3,991,601			2,917,276
Loss from operations		(933,323	)		(2,663,460	)		(4,017,907	)		(2,960,027	)
Other income (expense)
Interest expense		(690	)		(760,553	)		(279,697	)		(796,427	)
Amortization of debt discount		—			(57,604	)		(687,460	)		(157,980	)
Loss on related party transfer of intangible assets		—			(4,480,000	)		—			(4,480,000	)
Total other income (expense)		(690	)		(5,298,157	)		(967,157	)		(5,434,407	)
Net loss	$	(934,013	)	$	(7,961,617	)	$	(4,985,064	)	$	(8,394,434	)

Basic and Diluted Loss per Common Share	$	(0.01	)	$	(0.12	)	$	(0.06	)	$	(0.14	)

Weighted average number of common shares outstanding - basic and diluted		93,988,841			65,856,044			87,439,163			62,047,517


(The accompanying notes are an integral part of these consolidated financial statements)

		Three Months Ended December 31,						Six Months Ended December 31,
		2021			2020			2021		2020
Revenue	$	—		$	22,075		$	375		$37,460
Cost of revenue		—			17,588			—		28,131
Gross profit		—			4,487			375		9,329
Operating expenses
Professional fees		14,150			13,450			71,400		47,225
Research and development - related party		862,092			55,000			1,369,097		193,310
Research and development		600			10,000			600		10,700
Selling, general and administrative - related party		57,250			2,551			114,500		10,204
Selling, general and administrative		945,314			18,846			1,529,362		44,457
Total operating expense		1,879,406			99,847			3,084,959		305,896
Loss from operations		(1,879,406	)		(95,360	)		(3,084,584	)	(296,567)
Other income (expense)
Interest expense		(192,643	)		(30,968	)		(279,007	)	(35,874)
Amortization of debt discount		(545,781	)		(59,326	)		(687,460	)	(100,376)
Total other income (expense)		(738,424	)		(90,294	)		(966,467	)	(136,250)
Net loss	$	(2,617,830	)	$	(185,654	)	$	(4,051,051		$(432,817)
Basic and Diluted Loss per Common Share	$	(0.03	)	$	(0.00	)	$	(0.05	)	$(0.01)	)
Weighted average number of common shares outstanding - basic and diluted		86,928,431			60,249,492			84,226,110		60,146,776

(The accompanying notes are an integral part of these consolidated financial statements)

GLOBAL WHOLEHEALTH PARTNERS CORPORATION CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2022
	Common Stock				Additional Paid-in Capital		Common Stock Payable			Deferred Compensation			Retained Deficit			Total Stockholders' Equity (Deficit)
	Shares		Amount
BALANCE JULY 1, 2021	78,713,899	$	78,714	$	13,529,861	$	77,061		$	—		$	(13,782,732	)	$	(97,096	)
Common stock sold pursuant to the EMC2 SPA	3,438,484		3,438		799,748		—			—			—			803,186
Common stock issued upon conversion of convertible promissory note	250,000		250		76,811		(77,061	)		—			—			—
Common issued stock related to services	750,000		750		354,000		129,000			(96,750	)		—			387,000
Discount on convertible promissory notes due to beneficial conversion feature	—		—		538,200		—			—			—			538,200
Net loss for the three months ended September 30, 2021	—		—		—		—			—			(1,433,221	)		(1,433,221	)
Balance, September 30, 2021	83,152,383		83,152		15,298,620		129,000			(96,750	)		(15,215,953	)		198,069
Common stock sold pursuant to the EMC2 SPA	2,082,287		2,082		322,918		—			—			—			325,000
Common stock issued for to services	2,750,000		2,750		687,600		(129,000	)		32,250			—			593,600
Net loss for the three months ended December 31, 2021	—		—		—		—			—			(2,617,830	)		(2,617,830	)
Balance, December 31, 2021	87,984,670		87,984		16,309,138		—			(64,500	)		(17,833,783	)		(1,501,161	)
Common stock sold pursuant to the EMC2 SPA	2,335,743		2,335		74,535		—			—			—			76,870
Common stock issued for services	12,500,000		12,500		675,500		8,700			32,250			—			728,950
Common stock issued upon exercise of warrant	2,000,000		2,000		—		—			—			—			2,000
Common stock upon conversion of convertible promissory note principal	2,666,666		2,667		77,833		—			—			—			80,000
Net loss for the three months ended March 31, 2022	—		—		—		—			—			(934,013	)		(934,013	)
Balance, March 31, 2022	107,487,079	$	107,486	$	17,136,506	$	8,700		$	(32,250	)	$	(18,767,796	)	$	(1,547,354	)

	Common Stock					Additional Paid-in		Common Stock			Deferred			Retained			Total Stockholders' Equity
		Shares	Amount			Capital		Payable			Compensation			Deficit			(Deficit)
FOR THE SIX MONTHS ENDED DECEMBER 31, 2021
BALANCE JULY 1, 2021		78,713,899		$	78,714	$	13,529,861	$	77,061		$	—		$	(13,782,732	)	$	(97,096	)
Common stock sold pursuant to the EMC2 SPA		3,438,484			3,438		799,748		—			—			—			803,186
Common stock issued upon conversion of convertible promissory note		250,000			250		76,811		(77,061	)		—			—			—
Common issued stock related to services		750,000			750		354,000		129,000			(96,750	)		—			387,000
Discount on convertible promissory notes due to beneficial conversion feature		—			—		538,200		—			—			—			538,200
Net loss for the three months ended September 30, 2021		—			—		—		—			—			(1,433,221	)		(1,433,221	)
Balance, September 30, 2021		83,152,383			83,152		15,298,620		129,000			(96,750	)		(15,215,953	)		198,069
Common stock sold pursuant to the EMC2 SPA		2,082,287			2,082		322,918		—			—			—			325,000
Common stock issued for to services		2,750,000			2,750		687,600		(129,000	)		32,250			—			593,600
Net loss for the three months ended December 31, 2021		—			—		—		—			—			(2,617,830	)		(2,617,830	)
Balance, December 31, 2021		87,984,670		$	87,984	$	16,309,138	$	—		$	(64,500	)	$	(17,833,783	)	$	(1,501,161	)
FOR THE SIX MONTHS ENDED DECEMBER 31, 2020
BALANCE JULY 1, 2020		59,966,358		$	59,966	$	4,628,908	$	—		$	—		$	(4,748,609	)	$	(59,735	)
Common stock issued for cash		—			—		—		340,000			—			—			340,000
Discount on convertible promissory notes due to beneficial conversion feature		—			—		123,831		—			—			—			123,831
Net loss for the three months ended September 30, 2020		—			—		—		—			—			(247,163	)		(247,163	)
Balance, September 30, 2020		59,966,358			59,966		4,752,739		340,000			—			(4,995,772	)		156,933
Common stock issued for cash		—			—		—		90,000			—			—			90,000
Net loss for the three months ended December 31, 2020		—			—		—		—			—			(185,654	)		(185,654	)
Balance, December 31, 2020		59,966,358		$	59,966	$	4,752,739	$	430,000		$	—		$	(5,181,426	)	$	61,279

(The accompanying notes are an integral part of these consolidated financial statements)

GLOBAL WHOLEHEALTH PARTNERS CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)



FOR THE NINE MONTHS ENDED MARCH 31, 2021
BALANCE JULY 1, 2020	59,966,358	$	59,966	$	4,628,908	$	—		$	—	$	(4,748,609	)	$	(59,735	)
Common stock issued for cash	—		—		—		340,000			—		—			340,000
Discount on convertible promissory notes due to beneficial conversion feature	—		—		123,831		—			—		—			123,831
Net loss for the three months ended September 30, 2020	—		—		—		—			—		(247,163	)		(247,163	)
Balance, September 30, 2020	59,966,358		59,966		4,752,739		340,000			—		(4,995,772	)		156,933
Common stock issued for cash	—		—		—		90,000			—		—			90,000
Net loss for the three months ended December 31, 2020	—		—		—		—			—		(185,654	)		(185,654	)
Balance, December 31, 2020	59,966,358		59,966		4,752,739		430,000			—		(5,181,426	)		61,279
Common stock issued for cash	514,298		514		429,486		(430,000	)		—		—			—
Common stock issued upon conversion of convertible promissory note	146,486		147		55,503		—			—		—			55,650
Common stock issued for services	2,950,000		2,950		2,541,050		—			—		—			2,544,000
Common stock issued for license agreements with Charles Strongo	8,000,000		8,000		4,472,000		—			—		—			4,480,000
Common stock issued as compensation for financings	1,415,094		1,415		1,258,019		—			—		—			1,259,434
Net loss for the three months ended March 31, 2021	—		—		—		—			—		(7,961,617	)		(7,961,617	)
Balance, March 31, 2021	72,992,236	$	72,992	$	13,508,797	$	—		$	—	$	(13,143,043	)	$	438,746


(The accompanying notes are an integral part of these consolidated financial statements)

		Six Months Ended December 31,
		2021			2020
Cash flows from operating activities
Net loss	$	(4,051,051	)	$	(432,817	)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Common stock issued for services		980,600			—
Amortization of debt discount		687,460			100,376
Penalties on default of Firstfire Notes		191,400
Non cash lease expense		1,799
Depreciation and amortization		582			485
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable		—			(651	)
(Increase) decrease in prepaid expenses and other assets		(161,083	)		15,064
(Increase) decrease in inventory		(64,000	)		(83,869	)
Increase (decrease) in accounts payable and accrued expenses		217,670			(21,933	)
Increase (decrease) related party payables		368,979			(744	)
Net cash flows used in operating activities		(1,827,644	)		(424,089	)
Cash flows used in investing activity
Purchase of equipment		—			(3,505	)
Net cash flows used in investing activity		—			(3,505	)
Cash flows from financing activities
Proceeds from sale of common stock		1,400,000			430,000
Proceeds from convertible promissory notes		538,000			162,000
Payments of convertible promissory notes		(50,000	)		(73,000	)
Payments of promissory notes		(70,780	)		—
Proceeds from related party note, net		—			38,422
Payments of related party note		(2,785	)		(137,500	)
Net cash flows from financing activities		1,814,635			419,922
Change in cash		(13,009	)		(7,672	)
Cash at beginning of period		74,702			14,497
Cash at end of period	$	61,693		$	6,825
Supplemental disclosure of cash flow information:
Interest paid in cash	$	11,875		$	—
Income taxes paid in cash	$	—		$	—
Supplemental disclosure of non-cash transactions:
Debt discount recorded for beneficial conversion feature	$	356,656		$	—

(The accompanying notes are an integral part of these consolidated financial statements)

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

		Nine Months Ended March 31,
		2022			2021
Cash flows from operating activities
Net loss	$	(4,985,064	)	$	(8,394,434	)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Loss on related party transfer of intangible assets		—			4,480,000
Common stock issued for services		1,709,550			7,256,600
Amortization of debt discount		687,460			157,980
Penalties on default of Firstfire Notes		191,400			—
Non cash lease expense		3,598			—
Depreciation and amortization		873			776
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable		—			(651	)
(Increase) decrease in prepaid expenses and other assets		(115,929	)		(15,069	)
(Increase) decrease in inventory		(56,319	)		(2,911	)
Increase (decrease) in accounts payable and accrued expenses		213,411			(3,960	)
Increase (decrease) related party payables		410,229			(161	)
Net cash flows used in operating activities		(1,940,791	)		(496,861	)

Cash flows used in investing activity
Purchase of equipment		—			(3,505	)
Net cash flows used in investing activity		—			(3,505	)

Cash flows from financing activities
Proceeds from sale of common stock		1,478,870			430,000
Proceeds from convertible promissory notes		538,200			162,000
Payments of convertible promissory notes		(50,000	)		(73,000	)
Payments of promissory notes		(70,780	)		—
Proceeds from related party note, net		—			105,198
Payments of related party note		(2,785	)		(137,500	)
Net cash flows from financing activities		1,893,505			486,698
Change in cash		(47,286	)		(13,668	)
Cash at beginning of period		74,702			14,497
Cash at end of period	$	27,416		$	829

Supplemental disclosure of cash flow information:
Interest paid in cash	$	11,875		$	—
Income taxes paid in cash	$	—		$	—

Supplemental disclosure of non-cash transactions:
Common stock issued for conversion of note payable	$	80,000
Debt discount recorded for beneficial conversion feature	$	356,656		$	—

(The accompanying notes are an integral part of these consolidated financial statements)

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND ~~SIX~~NINE MONTHS ENDED ~~DECEMBER~~MARCH 31, ~~2021~~ 2022 AND ~~2020~~2021

NOTE 1 – Organization and Going Concern

Organization

Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation. The Company’s ticker symbol changed to GWHP.

The Company ~~sells and~~ develops in-vitro diagnostic products, including rapid diagnostic tests, such as the COVID-19 Test, 6-minute rapid whole blood Ebola Test, 6-minute whole blood Zika test, 8-minute whole blood rapid TB test and over 75 other tests.

Going Concern

The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $1,940,791 for the nine months ended March 31, 2022 and has an accumulated deficit of $18,767,796 from inception through March 31, 2022. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $1,827,644 for the six months ended December 31, 2021 and has an accumulated deficit of $17,833,783 from inception through December 31, 2021. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

NOTE 2 – Interim Statement Presentation

Basis of Presentation

The accompanying unaudited interim consolidated financial statements of Global Wholehealth Partners Corporation and its controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation (collectively, the “Company”), as of ~~December~~March 31, ~~2021~~2022, and for the three and ~~six~~nine months ended ~~December~~ March 31, 2022 ~~2021~~ and ~~2020~~2021 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2021 included in our Annual Report on Form 10-K filed with the SEC on September 27, 2021.

The accompanying unaudited interim Consolidated ~~Financial~~ Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of ~~December~~March 31, ~~2021~~ 2022, results of operations, stockholders’ equity and cash flows for the three and ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022 and ~~2020~~ 2022. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the accounting period. The Company considers its accounting policies relating to convertible debt to be the most significant accounting policy that involves management estimates and judgments. The Company has made accounting estimates based on the facts and circumstances available as of the reporting date. Actual amounts could differ from these estimates, and such differences could be material.

Information regarding the Company’s significant accounting policies is contained in Note 2, “Summary of significant accounting policies,” to the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2021. Presented below and in the following notes is supplemental information that should be read in conjunction with “Notes to Financial Statements” in the Annual Report.

Accounting Pronouncements

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.

New Accounting Pronouncements Not Yet Adopted

None.

Accounting Pronouncements Recently Adopted

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for the Company for fiscal years beginning after December 31, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company’s annual fiscal year. The Company adopted ASU 2020-06 beginning with our fiscal year starting on July 1, 2021 with no impact on its Financial Statements.

In January 2020, the FASB issued ASU 2020-01 - Investments - Equity securities (Topic 321), Investments - Equity method and joint ventures (Topic 323), and Derivatives and hedging (Topic 815) - Clarifying the interactions between Topic 321, Topic 323, and Topic 815. The amendments in this Update improve the accounting for certain equity securities upon the application or discontinuation of the equity method of accounting and clarify the scope considerations for forward contracts and purchased options on certain securities. The amendments are effective for public entities in fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2020-01 beginning with our fiscal year starting on July 1, 2021 with no impact on its Financial Statements.

910

In December 2019, the FASB issued ASU 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The Company adopted ASU 2019-12 effective July 1, 2021 with no impact on its Financial Statements.

NOTE 3 - Net Income (Loss) Per Share

The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The computation of diluted net income per share does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on earnings per share. Therefore, when calculating EPS if the Company experienced a loss, there is no inclusion of dilutive securities as their inclusion in the EPS calculation is antidilutive. Furthermore, options and warrants will have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options or warrants (they are in the money).

Following is the computation of basic and diluted net loss per share for the three and ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022 and ~~2020~~2021:

Schedule of basic and diluted net loss per share
		Three Months Ended March 31,			Nine Months Ended March 31,
		Three Months Ended December 31,						Six Months Ended December 31,
		2022		2021	2022		2021
		2021			2020			2021			2020
Basic and diluted EPS Computation
Basic and diluted EPS Computation
Numerator:
Numerator:
	Loss available to common stockholders'	$ (934,013)		$ (7,961,617)	$ (4,985,064)		$ (8,394,434)
Loss available to common stockholders'		$	(2,617,830	)	$	(185,654	)	$	(4,051,051	)	$	(423,817	)
Denominator:
Denominator:
	Weighted average number of common shares outstanding	93,988,841		65,856,044	87,439,163		62,047,517
Weighted average number of common shares outstanding			86,928,431			60,249,492			84,226,110			60,146,776
Basic and diluted EPS Computation		$ (0.01)		$ (0.12)	$ (0.06)		$ (0.14)
Basic and diluted EPS Computation		$	(0.03	)	$	(0.00	)	$	(0.05	)	$	(0.01	)
The shares listed below were not included in the computation of diluted losses
The shares listed below were not included in the computation of diluted losses
per share because to do so would be antidilutive for the periods presented:
per share because to do so would be antidilutive for the periods presented:
	Convertible notes	39,202,647		10,221	39,202,647		10,221
Convertible notes			15,090,127			388,629			15,090,127			388,629
	Warrants	546,975		2,000,000	546,975		2,000,000
Warrants			2,546,975			2,000,000			2,546,975			2,000,000
Total shares not included in the computation of diluted loss per share		39,749,622		2,010,221	39,749,622		2,010,221
Total shares not included in the computation of diluted loss per share			17,637,102			2,388,629			17,637,102			2,388,629

NOTE 3 – Stockholder’s Equity

Preferred Stock

The Company has Preferred stock: $0.001 par value; 10,000,000 shares authorized with no shares issued and outstanding.

Common Stock

The Company has 400,000,000 shares of Common ~~Stock~~ Stock authorized of which 87107,~~984~~587,~~670~~079 and 78,713,899 shares were issued and outstanding as of ~~December~~March 31, ~~2021~~2022 and June 30, 2021, respectively.

On April 20, 2021, the Company and Empire Associates, Inc. entered into a Stock Purchase Agreement whereby the Company agreed to issue 250,000 to Empire Associates, Inc. in full satisfaction of the $77,060 paid to Geneva by Empire Associates on behalf of the Company. The shares were issued on September 2, 2021, and are included in the calculation of EPS on an as-if issued basis.

On July 10, 2021, the Company and LionsGate Funding Management LLC (“LGFM”) entered into a Media and Marketing Services Agreement (the “MMSA”). Pursuant to the MMSA, 1) LGFM will provide services designed to increase the awareness and visibility in the investment community and market product to distributors throughout the world for a period of 12 months; and 2) the Company will pay LGFM $100,000 and issue 300,000 shares of restricted common stock valued at $129,000. The shares were issued on October 11, 2021 and are included in the calculation of EPS on an as-if issued basis. Lionsgate was issued 2,500,000 shares on January 13, 2022 in exchange for services valued at $215,000.

On July 22, 2020, the Company entered into a Common Stock Purchase Agreement (the “EMC2 SPA”) and a Registration Rights Agreement with EMC2 Capital, LLC (“EMC2 Capital”) pursuant to which EMC2 Capital agreed to invest up to One Hundred Million Dollars ($100,000,000) to purchase the Company’s common stock at a purchase price as defined in the Common Stock Purchase Agreement (the "Purchase Shares"). During the three months ended ~~December~~March 31, ~~2021~~2022, the Company sold 2,~~082~~335,~~287~~743 Purchase Shares to EMC2 Capital at prices ranging from $0.1202 - $0.~~20 and~~06 and received total proceeds of $~~325~~76,~~000~~871. During the ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022, the Company sold 57,~~520~~856,~~771~~514 Purchase Shares to EMC2 Capital at prices ranging from $0.1202 - $0.34 and received total proceeds of $1,~~400~~476,~~000~~872.

During the three months ended ~~December~~March 31, ~~2021~~2022, the Company issued 212,~~750~~500,000 shares in exchange for services valued at $~~690~~688,~~350~~000 inclusive of 9,000,000 shares issued to Board members valued at $387,000. During the ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022, the Company issued 316,~~500~~000,000 shares in exchange for services valued at $1,~~045~~733,100.

During the three months ended March 31, 2022, EMC2 exercised their warrant to purchase 2,000,000 shares in exchange for the exercise price of $2,000.

During the three months ended March 31, 2022, Firstfire converted $80,000 or principal of Firstfire Note No. 1 at a per share price of $0.03, and received 2,666,666 shares of common stock.

Warrants

Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. A summary of the Company’s warrants outstanding and exercisable as of ~~December~~March 31, ~~2021~~2022 and June 30, 2021 is as follows:

Summary of the warrants
	Shares of Common Stock Issuable from Warrants Outstanding as of		Weighted Average
Description	~~December~~March 3031,	June 30,	Exercise Price	Date of	Expiration
	2021	2021		Issuance
	2022	2021		Issuance
EMC2 Capital	~~2,000,000~~-	2,000,000	variable	July 22, 2020	July 22, 2025
Geneva	51,975	51,975	variable	April 26, 2021	April 26, 2024
Firstfire Warrant 1	165,000	165,000	variable	June 18, 2021	June 18, 2024
Firstfire Warrant 2	330,000	-	variable	August 27, 2021	August 27, 2024
Total	2,546,975	2,216,975

NOTE 4 –Transactions with Related Persons

On July 10, 2021, the Company and LionsGate Funding Management LLC (“LGFM”) entered into a Media and Marketing Services Agreement (the “MMSA”). Pursuant to the MMSA, 1) LGFM will provide services designed to increase the awareness and visibility in the investment community and market product to distributors throughout the world for a period of 12 months. Pursuant to the MMSA, during the six months ended December 31, 2021, the Company paid LGFM $100,000 and issued 300,000 shares of restricted common stock.

On July 1, 2021, the Company paid LionsGate Funding Group LLC (“LionsGate”) $24,000 or $21,215 in excess of the balance owing to LionsGate which the Company recorded as a receivable. During the three and six months ended December 31, 2021, LionsGate made payments on behalf of the company totaling $950 leaving a receivable balance of $20,265.

Beginning in January 2020, the Company utilizes the R&D capabilities of Pan Probe Biotech to perform studies and perform work towards development of the Company’s COVID-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe. During the three months ended December 31, 2021, the Company incurred R&D costs of $862,092 and paid Pan Probe $400,000 for R&D work. During the three months ended December 31, 2020, the Company incurred R&D costs of $55,000 and paid Pan Probe $55,000 for R&D work. During the six months ended December 31, 2021, the Company incurred R&D costs of $1,369,097 and paid Pan Probe $1,000,000 for R&D work. During the six months ended December 31, 2020, the Company incurred R&D costs of $190,000 and paid Pan Probe $190,000 for R&D work. As of December 31, 2021 and June 30, 2021 the balance due to Pan Probe was $597,577 and $228,480, respectively.

The Company paid rent to Pan Probe on a temporary basis, from April 21, 2020 through October 21, 2020, at a rate of $2,551 per month or $15,306 which was prepaid in full in April 2020. During the three and six months ended December 31, 2020, the Company recognized $2,551 and $10,204 of rent expense related to this arrangement.

Related Party Note

From time-to-time the Company receives shareholder advances from LionsGate to cover operating costs. On March 29, 2020, the Company issued a Promissory Note (the “Note”), and on June 30, 2020, amended the Note (the “Note Amendment”). Pursuant to the Note and Note Amendment, the terms provided for total funding of up to $585,000, interest at the rate of 5% per annum with the principal and interest due in-full on June 30, 2021. On January 27, 2021, the Company and LionsGate entered into a Loan Agreement (the “Loan Agreement”) and Promissory note (the “Promissory Note”) pursuant to which the Company may borrow up to $250,000 at an annual interest rate of 5% and default interest rate of 15%. The Loan Agreement supersedes the Note and Note Amendment and included a beginning balance of $29,951 which was the balance of advances and accrued interest owing under the Note as of January 27, 2021. The Promissory Note matured on December 31, 2021. During the three months ended December 31, 2021 and 2020, LionsGate provided advances totaling $950 and $14,012, respectively. During the six months ended December 31, 2021 and 2020, LionsGate provided advances totaling $950 and $38,422, respectively.

During the three and six months ended December 31, 2020, the Company repaid LionsGate $27,500 and $137,500, respectively. During the three and six months ended December 31, 2021, the Company repaid LionsGate $0 and $24,000, respectively. During the six months ended December 31, 2021, under the Promissory Note, the Company mistakedly made an overpayment to LionsGate in the amount of $21,215 to which the Company applied $950 of advances leaving a receivable balance due from Lionsgate of $20,265 as of December 31, 2021.

During the three and six months ended December 31, 2020, the Company recognized $217 and $628, respectively, of interest expense related to the Note.

Lionsgate was issued 2,500,000 shares on January 13, 2022 in exchange for services valued at $215,000.

On July 1, 2021, the Company paid LionsGate Funding Group LLC (“LionsGate”) $24,000 or $21,215 in excess of the balance owing to LionsGate which the Company recorded as a receivable. During the three and nine months ended March 31, 2022, LionsGate made payments on behalf of the company totaling $950 leaving a receivable balance of $20,265.

Beginning in January 2020, the Company utilizes the R&D capabilities of Pan Probe Biotech to perform studies and perform work towards development of the Company’s COVID-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe. During the three months ended March 31, 2022, the Company incurred no R&D costs and made payments to Pan Probe totaling $15,000. During the nine months ended March 31, 2022, the Company incurred R&D costs of $1,369,097 and paid Pan Probe $1,015,000 for R&D work. During the six months ended March 31, 2021, the Company paid Pan Probe $190,000 for R&D work. As of March 31, 2022 and June 30, 2021 the balance due to Pan Probe was $582,577 and $228,480, respectively.

The Company paid rent to Pan Probe on a temporary basis, from April 21, 2020 through October 21, 2020, at a rate of $2,551 per month or $15,306 which was prepaid in full in April 2020. During the six months ended March 31, 2021, the Company recognized $10,204 of rent expense related to this arrangement.

Related Party Note

From time-to-time the Company receives shareholder advances from LionsGate to cover operating costs. On March 29, 2020, the Company issued a Promissory Note (the “Note”), and on June 30, 2020, amended the Note (the “Note Amendment”). Pursuant to the Note and Note Amendment, the terms provided for total funding of up to $585,000, interest at the rate of 5% per annum with the principal and interest due in-full on June 30, 2021. On January 27, 2021, the Company and LionsGate entered into a Loan Agreement (the “Loan Agreement”) and Promissory note (the “Promissory Note”) pursuant to which the Company may borrow up to $250,000 at an annual interest rate of 5% and default interest rate of 15%. The Loan Agreement supersedes the Note and Note Amendment and included a beginning balance of $29,951 which was the balance of advances and accrued interest owing under the Note as of January 27, 2021. The Promissory Note matured on December 31, 2021. During the three months ended March 31, 2022 2021, LionsGate provided advances totaling $0 and $66,776, respectively. During the six months ended March 31, 2022 and 2021, LionsGate provided advances totaling $0 and $106,698, respectively.

During the three and nine months ended March 31, 2022, the Company repaid LionsGate $0 and $24,000, respectively. During the three and nine months ended March 31, 2021, the Company repaid LionsGate $0 and $137,500, respectively. On July 1, 2021, under the Promissory Note, the Company mistakedly made an overpayment to LionsGate in the amount of $21,215 to which the Company applied $950 of advances leaving a receivable balance due from Lionsgate of $20,265 as of March 31, 2022.

During the three and nine months ended March 31, 2021, the Company recognized $584 and $1,212, respectively, of interest expense related to the Note.

NOTE 5 – Convertible Promissory Notes

On April 18, 2020, the Company issued five separate unsecured convertible promissory notes in exchange for $95,000 (the "Convertible Notes"). Each Convertible Note contains the same terms and conditions. The Convertible Notes bear interest of 8%, matured in six months on October 17, 2020 and are convertible at any time into shares of restricted common stock at a conversion price of $9.00 per share. The notes are currently in default. The debt discount attributable to the fair value of the beneficial conversion feature amounted to $42,224 for the Convertible Notes and was accreted over the term of the Convertible Notes. In December of 2020, the Company repaid, in-full, two of the Convertible Notes with principal a balance totaling $10,000 and $500 of interest payable. In November of 2021, the Company repaid, in-full, one of the Convertible Notes with principal a balance totaling $50,000 and $6,425 of interest payable. During the three months ended ~~December~~March 31, ~~2021~~2022 and ~~2020~~2021, the Company recognized $~~1,243~~690 and $1,~~855~~677, respectively, of interest expense; and $0 ~~and~~ and $3,922, respectively, of accretion. During the ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022 and ~~2020~~2021, the Company recognized $23,~~957~~647 and $35,~~771~~448, respectively, of interest expense; and $0 and $25,149, respectively, of accretion. As of ~~December~~March 31, ~~2021~~2022, the Convertible ~~Notes~~ Notes principal balance is $35,000 and accrued interest balance is $4,716

Firstfire Global Opportunities Fund LLC

Firstfire Note No. 1

On June 18, 2021, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund LLC ("Firstfire"), for the sale of a secured, 12% senior secured convertible promissory note in the principle amount of $275,000 and 165,000 stock purchase warrants. On July 8, 2021, the Company received $224,500 net of a $25,000 original issue discount and $25,500 of placement agent and legal fees, and issued a senior secured convertible promissory note (the "Firstfire Note No. 1") in the amount of $275,000. The terms of the Firstfire Note No. 1 provide for all principal and interest due in twelve (12) months on June 18, 2022, with $33,000 of interest (i.e., $275,000 x 12%) earned as of June 18, 2021, interest due upon default of 20% annually, a prepayment penalty of 5% of all outstanding amounts due, and if the Company triggers and event of default which is not cured, then the total of all amounts owing will be increased by 25%, to be paid at the discretion of Firstfire, in the form of cash or conversion into common stock. The Firstfire Note No. 1 is convertible any time after June 18, 2021 into shares of common stock at a conversion price that is the lesser of $0.35 per share or seventy percent (70%) of the lowest traded price of our common stock during the ten (10) trading day period prior to conversion. Conversion of the Firstfire Note No. 1 and/or the Firstfire Warrant No. 1 is limited to Firstfire beneficially owning no more than 4.99% of the outstanding common stock of the Company.

Additionally, the Company entered into a Registration Rights Agreement with Firstfire whereby the Company agreed to file within 90 days and have declared effective within 120 days from June 18, 2021, a registration statement to cover the shares issuable under the Firstfire Note No. 1 and Firstfire Warrant No. 1. Failure to file within 90 days and have the registration declared effective before 120 days will result in liquidated damages of 1% principal amount.

Due to the Company not filing a registration statement to cover the shares underlying a Firstfire Note No. 1 conversion by the dates specified in the Registration Rights Agreement, the Firstfire Note No. 1 fell into default resulting in the Firstfire Note No. 1 becoming immediately due and the Company recognizing liquidated damages of $2,750 and $77,000 increase in the amount due.

As additional consideration, the Company granted Firstfire a warrant to purchase 165,000 shares of our common stock (the "Firstfire Warrant No. 1") at an exercise price of $0.50 for a period of three (3) years. The Firstfire Warrant No. 1 contains provision for an anti-dilution adjustment and cashless exercise rights if a registration statement covering the resale of the Firstfire Warrant No. 1 shares is not available for the resale of such Firstfire Warrant No. 1 shares. The fair value of the Firstfire Warrant No. 1 was $0.36 per share and was calculated using the Black-Scholes option pricing model with the following assumptions: (1) Stock price of $0.41 per share; (2) exercise price of $0.50 per share; (3) discount rate 0.47% (4) expected life of 3 years, (5) expected volatility of 194.5%, and (6) zero expected dividends. This resulted in allocating $48,849 to the Firstfire Warrant No. 1 and $226,151 to the Firstfire Note No. 1. Then, we calculated the debt discount attributable to the beneficial conversion feature which amounted to $264,372. As a result of the original issue discount, fees, warrant and beneficial conversion feature of the Firstfire Note No. 1, the Company recorded a debt discount of $275,000.

AsDuring ofthe ~~September~~three 30months ended March 31, ~~2021~~2022, ~~the~~Firstfire converted $80,000 or principal of Firstfire Note No. 1 is ~~convertible~~at ~~into~~a 1per share price of $0.03,~~795~~ and received 2,~~918~~666,666 shares of common stock.

1314

Firstfire Note No. 2

On August 27, 2021, the Company entered into a Securities Purchase Agreement with Firstfire, for the sale of a secured, 12% senior secured convertible promissory note in the principle amount of $385,000 and 330,000 stock purchase warrants. The Company received $313,700 net of a $35,000 original issue discount and $36,300 of placement agent and legal fees, and issued a senior secured convertible promissory note (the "Firstfire Note No. 2") in the amount of $385,000. The terms of the Firstfire Note No. 2 provide for all principal and interest due in twelve (12) months on August 27, 2022, with $46,200 of interest (i.e., $385,000 x 12%) earned as of August 27, 2021, interest due upon default of 20% annually, a prepayment penalty of 5% of all outstanding amounts due, and if the Company triggers and event of default which is not cured, then the total of all amounts owing will be increased by 25%, to be paid at the discretion of Firstfire, in the form of cash or conversion into common stock. The Firstfire Note No. 2 is convertible any time after August 27, 2021 if the underlying shares have an effective registration statement, otherwise, the right of conversion commences after 180 days from August 31, 2021 into shares of common stock at a conversion price that is the lesser of $0.35 per share or seventy percent (70%) of the lowest traded price of our common stock during the ten (10) trading day period prior to conversion. Conversion of the Firstfire Note No. 2 and/or the Firstfire Warrant No. 2 is limited to Firstfire beneficially owning no more than 4.99% of the outstanding common stock of the Company.

Additionally, the Company entered into a Registration Rights Agreement with Firstfire whereby the Company agreed to file within 90 days and have declared effective within 120 days from August 27, 2021, a registration statement to cover the shares issuable under the Firstfire Note No. 2 and Firstfire Warrant No. 2. Failure to file within 90 days and have the registration declared effective before 120 days will result in liquidated damages of 1% of the principal amount.

Due to the Company not filing a registration statement to cover the shares underlying a Firstfire Note No. 2 conversion by the dates specified in the Registration Rights Agreement, the Firstfire Note No. 2 fell into default resulting in the Firstfire Note No. 2 becoming immediately due and the Company recognizing liquidated damages of $3,850 and $107,800 increase in the amount due.

As additional consideration, the Company granted Firstfire a warrant to purchase 330,000 shares of our common stock (the "Firstfire Warrant No. 2") at an exercise price of $0.50 for a period of three (3) years. The Firstfire Warrant No. 2 contains provision for an anti-dilution adjustment and cashless exercise rights if a registration statement covering the resale of the Firstfire Warrant No. 2 shares is not available for the resale of such Firstfire Warrant No. 2 shares. The fair value of the Firstfire Warrant No. 2 was $0.32 per share and was calculated using the Black-Scholes option pricing model with the following assumptions: (1) Stock price of $0.37 per share; (2) exercise price of $0.50 per share; (3) discount rate 0.41% (4) expected life of 3 years, (5) expected volatility of 184.0%, and (6) zero expected dividends. This resulted in allocating $82,870 to the Firstfire Warrant No. 2 and $302,130 to the Firstfire Note No. 2. Then, we calculated the debt discount attributable to the beneficial conversion feature which amounted to $248,111. As a result of the original issue discount, fees, warrant and beneficial conversion feature of the Firstfire Note No. 2, the Company recorded a debt discount of $385,000.

During the three and ~~six~~nine months ended ~~December~~March 2131, ~~2021,~~ 2022, the Company recognized interest expense related to the stated interest described in Firstfire Note No. 1 and Firstfire Note No. 2 (collectively, the “Firstfire Notes”) of $0 and $79,200, respectively. During the three and ~~six~~nine months ended ~~December 21~~March 31, ~~2021~~2022, the Company recognized interest expense related to the 25% default penalty and 1% liquidated damages of $191,400. In addition, the Company recognized the accretion of the debt discount on the Firstfire Notes during the three and ~~six~~nine months ended ~~December~~March 31, ~~2021~~ 2022 of $~~545,781~~0 and $660,000, respectively.

As of ~~December~~March 31, ~~2021~~2022, the Firstfire Note No. 1 ~~and~~ and No. 2 are convertible into 1839,~~991~~198,~~836~~000 shares of common stock.

Geneva Promissory Note dated April 26, 2021

On April 26, 2021, the Company and Geneva Roth Remark Holdings, Inc. ("Geneva") entered into a Securities Purchase Agreement (the "SPA"). Pursuant to the SPA, The Company sold to Geneva a Promissory Note for the principal amount of $86,625 (the "Geneva Promissory Note ") and issued a warrant to purchase up to 51,975 shares of common stock (the “Geneva Warrant”). Under the Geneva Promissory Note the Company received net proceeds of $75,000 which included deductions for a 10% original issue discount, $3,000 for legal fees and $750 as a due diligence fee. The Geneva Promissory Note matured in one (1) year, requires ten (10) monthly payments of $9,529 beginning June 1, 2021, and is unsecured. On August 9, 2021, the Company repaid, in whole, the balance due under the Geneva Promissory Note, or $57,173.

1415

During the ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022, the ~~Company~~ Company made payments totaling $76,230 including principal of $70,780 and interest of $5,450, and recognized accretion of the debt discount of of $27,460.

Geneva Convertible Promissory Notes dated July 13, 2020, August 3, 2020 and September 8, 2020

On July 13, 2020, August 3, 2020 and September 8, 2020 (the “Issue Dates”), the Company and Geneva entered into separate and identical Securities Purchase Agreements (the "Geneva SPAs"). Pursuant to the Geneva SPAs, Geneva and the Company entered into separate and identical Convertible Promissory Notes also dated as of July 13, 2020, August 3, 2020 and September 8, 2020 for principal amounts of $63,000, $55,000 and $53,000, respectively (the "Geneva CPNs"). Pursuant to the terms of the Geneva CPNs, the Company received net proceeds of $60,000, $52,000 and $50,000 (the proceeds from each note were funded net of $3,000 in legal fees). The Geneva CPNs matured in one year, accrued interest of 10% and, after 180 days, were convertible into shares of common stock any time at a conversion price equal to 58% of the lowest trading price during the twenty-trading day period ending on the latest complete trading day prior to the conversion date. The Geneva CPN’s may be prepaid anytime up to 180 days from issuance with the following prepayment penalties: 1) The period beginning on the Issue Date and ending on the date which is ninety (90) days following the Issue Date, 125%; 2) The period beginning on the date that is ninety-one (91) day from the Issue Date and ending one hundred fifty (150) days following the Issue Date, 135%; and 3) The period beginning on the date that is one hundred fifty-one (151) day from the Issue Date and ending one hundred eighty (180) days following the Issue Date, 139%.

On December 21, 2020, the Company paid $90,487 as full payment of the Geneva CPN dated July 13, 2020. The payment included $63,000 of principal, $2,917 of interest related to the coupon and $24,570 as a prepayment penalty recorded as interest expense.

On February 16, 2021, Empire Associates, Inc., an unaffiliated company, paid off the balance, in-full, on the note dated August 3, 2020. The payment totaled $77,061 and included $55,000 of principal, $3,256 of interest related to the coupon and $18,805 as a prepayment penalty recorded as interest expense. At the time of payoff, the Company and Empire Associates, Inc. had not entered into any agreements related to the payment of the Geneva CPN dated August 3, 2020. On April 20 the Company and Empire Associates, Inc. entered into a Stock Purchase Agreement whereby the Company agreed to issue 250,000 to Empire Associates, Inc. in full satisfaction of the $77,061 paid to Geneva on behalf of the Company.

On March 15, 2021, the Company issued 146,486 shares of common stock to Geneva upon their conversion, in-full, of $53,000 of Principal and $2,650 of unpaid interest owing under the Geneva CPN dated September 8, 2020.

The debt discount attributable to the legal fees paid and fair value of the beneficial conversion feature contained in the Geneva CPNs amounted to $132,831 and was accreted over the term of the Geneva CPNs. In the event a Geneva CPN was paid in advance of its maturity date, the future accretion was recorded in the period the related Geneva CPN was repaid.

The Geneva CPNs were repaid in full in fiscal 2021. During the three and six months ended December 31 2020, the Company recognized $4,604 and $7,173 of interest expense, and $59,326 and $79,149, respectively, of accretion related to the debt discount.

NOTE 6 - Leases

On September 14, 2021, the Company leased 6,900 square feet of office and light industrial space located at 1130 Calle Cordillera, San Clemente, California and entered into a Standard Multi-Tenant Office Lease (the “Lease”). Pursuant to the Lease the term is five years beginning on October 15, 2021, the Company paid a security deposit of $32,621, and monthly base rent is $9,696 subject to an annual increase of 3% each year.

As of ~~December~~March 31, ~~2021~~2022, the Company has ~~not~~ not entered into any leases other than the lease described above which have not yet commenced and would entitle the Company to significant rights or create additional obligations.

The components of lease expenses are as follows:

Schedule of lease cost
	Three Months Ended December 31,
		2021		2020
Operating lease cost	$	30,887	$	—

	Three Months Ended March 31,
	2022		2021
Operating lease cost	$	30,887	$	—

Supplemental balance sheet information related to the Lease is as follows:

	December 31, 2021
	March 31, 2022
Operating lease right-of-use asset	$	~~498~~476,~~672~~125
Current maturities of operating lease	$	8688,~~009~~347
Non-current operating lease		~~414~~391,~~462~~375
Total operating lease liabilities	$	~~500~~479,~~471~~722
Weighted Average remaining lease term (in years):		4.7954
Discount rate:		6.76	%

The Company’s future lease payments, which are presented as current maturities of operating leases and non-current operating lease liabilities on the Company’s balance sheets as of ~~December~~March 31, ~~2021~~2022 are as follows:

Schedule of future lease payments		Amount
		Amount
2022 remaining	$	$29,089	~~87,268~~
2023		118,975	~~119,848~~
2024		122,544	~~123,443~~
2025		126,220	~~127,146~~
2026		130,007	~~130,961~~
Total lease payments			588,666
2027		32,740
Less: Imputed interest			(88,195	)
Total lease payments		559,575
Total lease obligation			500,471
Less: Imputed interest		(79,853)
Less: current lease obligations			86,009
Total lease obligation		479,722
Long term lease obligations		$	414,462
Less: current lease obligations		88,347
Long term lease obligations	$	391,375

NOTE 7 – Commitments and Contingencies

On September 14, 2021, the Company leased 6,900 square feet of office and light industrial space located at 1130 Calle Cordillera, San Clemente, California. See “Note 6 - Leases” for additional information.

~~COVID-19 Pandemic~~ On February 17, 2022, the Securities and Exchange Commission filed a lawsuit in the ~~Coronavirus~~federal ~~Aid~~district court for the Southern District of California, ~~Relief~~charging the Company, former CEO Charles Strongo, and ~~Economic~~four ~~Security~~stock promoters with violations of section 10(~~“CARES”~~b) of the Securities Exchange Act of 1934 and section 17(a) of the Securities Act of 1933. The SEC’s complaint seeks injunctive relief, disgorgement of funds allegedly received from illegal conduct plus pre-judgment interest, and the civil penalties. On the same day, the US Attorney’s Office for the Southern District of California announced the unsealing of an indictment charging Mr. Strongo and the promoters with conspiring to manipulate the market for the Company’s in an alleged “pump-and-dump” scheme through allegedly false and misleading statements in press releases and SEC filings concerning the Company’s emergency use authorization submissions to the Food and Drug Administration for COVID-19 tests. Mr. Strongo adamantly denies the allegations and has entered a plea of not guilty to the charges. Due to the nature and early stage of the SEC Action, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic may have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2022.

The pandemic may adversely affect our operations, our employees and our employee productivity. It may also impact the ability of our subcontractors, partners, and suppliers to operate and fulfill their contractual obligations, and result in an increase in costs, delays or disruptions in performance. Our employees are working remotely and using various technologies to perform their functions. In reaction to the spread of COVID-19 in the United States, many businesses have instituted social distancing policies, including the closure of offices and worksites and deferring planned business activity. The disruption and volatility in the global and domestic capital markets may increase the cost of capital and limit our ability to access capital. Both the health and economic aspects of the COVID-19 virus are highly fluid and the future course of each is uncertain. For these reasons and other reasons that may come to light if the coronavirus pandemic and associated protective or preventative measures expand, we may experience a material adverse effect on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.

On March 27, 2020, then President Trump signed into law the CARES Act. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also appropriated funds for the SBA Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by COVID-19.

NOTE 8 – Subsequent Events

Management has reviewed material events subsequent of the period ended ~~December~~March 31, ~~2021~~2022 and prior to the filing of our consolidated financial statements in accordance with FASB ASC 855 “Subsequent Events”.

On January 13, 2022, the Board of Directors declared a dividend of two shares of common stock for each one share of common stock of the Company. The record date will be March 31, 2022 and the payable date will be April 1, 2022.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Report on Form 10-Q contains forward-looking statements which involve assumptions and describe our future plans, strategies, and expectations, and are generally identifiable by use of words such as “may” “will” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project,” or the negative of these words or other variations on these words or comparable terminology. These statements are expressed in good faith and based upon a reasonable basis when made, but there can be no assurance that these expectations will be achieved or accomplished.

Such forward-looking statements include statements regarding, among other things, (a) the potential markets for our products, our potential profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in the in-vitro diagnostics industry, (d) our future financing plans, and (e) our anticipated needs for working capital. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as in this Form 10-Q generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. In addition to the information expressly required to be included in this filing, we will provide such further material information, if any, as may be necessary to make the required statements, in light of the circumstances under which they are made, not misleading.

Although forward-looking statements in this report reflect the good faith judgment of our management, forward-looking statements are inherently subject to known and unknown risks, business, economic and other risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, other than as may be required by applicable law or regulation. Readers are urged to carefully review and consider the various disclosures made by us in our filings with the Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect our actual results may vary materially from those expected or projected.

Except where the context otherwise requires and for purposes of this Form 10-Q only, “we” “us“ “our“ “Company“ “our Company“ and “Global WholeHealth Partners” refer to Global WholeHealth Partners Corporation, a Nevada corporation.

Our Business

We sell and develop in-vitro diagnostic products, including rapid diagnostic tests, such as the COVID-19 test, 6-minute rapid whole blood Ebola test, 6-minute whole blood Zika test, 8-minute whole blood rapid TB test and over 75 other tests more than 40 which are FDA approved.

The Company was founded to develop and market in-vitro diagnostic (“IVD”) tests for over-the-counter (“OTC” or consumer), or consumer-use and point-of-care (“POC” or professional) which includes hospitals, physicians’ offices and medical clinics, including those within penal systems throughout the US and abroad. The Company currently markets a range of diagnostic test kits for consumer use through OTC sales, and for use by health care professionals, generally located at medical clinics, physician offices and hospitals known POC, in the United States. These test kits are known as in-vitro diagnostic test kits or IVD products.

All of the products we sell are manufactured in a U.S. Food and Drug Administration (“FDA”) Approved Facility in the USA. An FDA Approved facility is a facility that meets Good Manufacturing Practices (“GMP”) with the FDA.

We sell products internationally which are not FDA approved to sell in the US. These products include an FDA Certificate of Exportability and include tests such as Ebola, ZIKA, Dengue, Malaria, Influenza, Tuberculosis, Corona Viruses, and other vector borne diseases.

As a result of the COVID-19 pandemic, the Company became laser focused on developing and selling COVID tests beginning in the second half of fiscal 2020. The Company achieved sales of COVID tests in fiscal 2021 that were sourced from third parties. In addition, over the course of fiscal 2021, the Company continued its efforts to develop an RDT, RT-PCR and antigen test. Due to the relatively quick commoditization of COVID-19 tests, the Company’s strategy of selling third party tests until it could complete a COVID test of its own proved ill-timed and caused a drop in sales in the latter part of fiscal 2021. As a result, the Company refocused its attention on marketing its core FDA OTC approved products which includes tests for pregnancy, ovulation, colorectal, drugs of abuse, glucose strips and glucose monitors through various platforms, including Walmart, Amazon and eBay, in addition to the development of a COVID antigen test being developed under a Memorandum of Understanding (“MOU”) dated September 15, 2021 between Global WholeHealth Partners, Avant Gen, Inc. and Pan Probe Biotech. Pursuant to the MOU, the parties thereto have developed a rapid Covid-19 antigen test. The work under the MOU has resulted in the filing of clinical studies with the NIH and we are hoping to receive an FDA EUA approval in fiscal Q3. In addition, the Company has developed a saliva based rapid COVID-19 test not subject to the MOU which the company plans to file with the NIH seeking an FDA EUA which the Company hopes to receive in fiscal Q4.

The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

As of ~~December~~March 31, ~~2021~~2022, we had negative ~~working~~ working capital of $1,~~624~~671,~~848~~290, a cash balance of $6127,~~693~~416 and inventory balance of $9386,~~681~~000. Management recognizes that in order for us to meet our capital requirements, and continue to operate, additional financing will be necessary. We expect to raise additional funds ~~through~~ through private or public equity investment in order to expand the range and scope of our business operations. We will seek access to ~~private~~ private or public equity but there is no assurance that such additional funds will be available for us to finance our operations on acceptable terms, if at all. If we are unable to raise additional capital or generate positive cash flow, it is unlikely that we will be able to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Results of Operations

Three and ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022 compared with the three and ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021

Revenue and Cost of Revenue

During the three months ended March 31, 2022 and 2021, the Company’s sales totaled $7,000 and $2,460, respectively with cost of sales of $33,681 and $54,540, respectively. During the nine months ended March 31, 2022 and 2021, the Company’s sales totaled $7,375 and $39,920, respectively.

During the three months ended March 31, 2022 and 2021, the Company’s cost of revenue totaled $33,681 and $54,540. During the nine months ended March 31, 2022 and 2021, the Company’s cost of revenue totaled $33,681 and $82,671, respectively. The elevated cost of revenue was due to the fair value adjustment to inventory for the shelf-life expiration of some products which totaled $29,681 and $51,615 during the three and nine months ended March 31, 2022 and 2021, respectively, resulting in negative gross profit.

Operating Expenses

	Three Months Ended December 31,								Increase /
			Three Months Ended March 31,							Increase /
	2021				2020				(Decrease)
			2022				2021			(Decrease)
Operating expenses:
Professional fees	$	~~14,150~~	$	32,132	$	~~13,450~~	$	14,400	~~$700~~	$17,732
Research and development		~~862,692~~		3,000		~~65,000~~		30,000	~~797,692~~	(27,000)
Selling, general and administrative		~~408,964~~		142,560		~~21,397~~		22,980	~~387,567~~	119,580
Stock compensation		~~593,600~~		728,950		—		2,544,000	~~593,600~~	(1,815,050)
Total operating expenses	$	~~1,879,406~~	$	906,642	$	~~99,847~~	$	2,611,380	~~$1,779,559~~	$(1,704,738)

	Six Months Ended December 31,				Increase /
	2021		2020		(Decrease)
Operating expenses:
Professional fees	$	71,400	$	47,225	$24,175
Research and development		1,369,697		204,010	1,165,687
Selling, general and administrative		663,262		54,661	608,601
Stock compensation		980,600		—	980,600
Total operating expenses	$	3,084,959	$	305,896	$2,779,063

	Nine Months Ended March 31,				Increase /
	2022		2021		(Decrease)
Operating expenses:
Professional fees	$	103,532	$	61,625	$41,907
Research and development		1,372,697		234,010	1,138,687
Selling, general and administrative		805,822		77,641	728,181
Stock compensation		1,709,550		2,544,000	(834,450)
Total operating expenses	$	3,991,601	$	2,917,276	$1,074,325

Professional Fees

Professional fees relate to expenditures incurred primarily for legal and accounting services. During the ~~six~~three and nine months ended ~~December~~March 31, ~~2021~~2022 compared to the ~~six~~three and nine months ended ~~December~~ March 31, ~~2020~~2021 professional fees increased primarily due to increased fees for accounting and legal services ~~of approximately $14,000 and $10,000, respectively~~.

Research and Product Development

Research and Product Development (“R&D”) costs represent costs incurred to develop our tests and are incurred pursuant to certain internal R&D cost allocations, when applicable, and agreements with third-party providers, but primarily with Pan Probe Biotech, owned by Dr. Shujie Cui, our Chief Science Officer. R&D costs are expensed when incurred. During the three and ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022 compared to the three and ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021, R&D costs increased due to the development of a COVID antigen test. The timing of the development costs is not expected to be consistent from period to period.

Selling, General and Administrative

Selling, general and administrative (“SG&A”) costs include all expenditures related to personnel, rent, travel, public company costs, utilities, marketing and other office related costs. SG&A costs increased ~~by $387,567 to $408,964~~ during the three months ended December 31, 2021 compared to $21,397 during the three months ended December 31, 2020. The increase is primarily due to an increase of $313,000 in personnel costs, $42,000 in marketing costs and ~~$33,000~~nine ~~increase in other administrative costs. SG&A costs increased by $608,601 to $663,262 during the six~~ months ended ~~December~~March 31, ~~2021~~2022 ~~compared~~over ~~to $54,661 during~~ the ~~six~~prior ~~months~~year ~~ended December 31, 2020. The increase is~~ primarily ~~due~~ todue anincreases ~~increase of $398,000~~ in personnel costs, ~~$181,000 in~~ marketing costs ~~and $30~~,~~000~~ ~~increase~~rent in other administrative costs.

Stock Compensation

Stock compensation represents the expense associated with the issuance of stock in exchange for services and is non-cash in nature. Stock compensation is based on our stock price at the measurement date and fluctuates as our stock price changes. During the three months ended ~~December~~March 31, ~~2021~~2022, the Company issued 212,~~750~~500,000 shares of common stock valued at $~~690~~688,~~350~~000 and recognized $32,250 of deferred stock compensation and $8,700 for unissued shares. During the ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022, the Company issued 316,~~500~~000,000 shares of common stock valued at $1,~~045~~733,~~100~~000 and recognized $96,750 of deferred stock compensation and $8,700 for unissued shares with $6432,~~500~~250 to be recognized over the ~~remaining~~final ~~two~~fiscal ~~quarters~~quarter of ~~fiscal~~ 2022 ~~at $32,250 per quarter~~.

Other Income and (Expense)

Other expense includes “interest expense” which relates to the stated interest and penalties upon default of our outstanding promissory notes, and “amortization of debt discount” which represents the accretion of the discount applied to our notes as a result of the issuance of detachable warrants and the beneficial conversion feature contained certain notes. During the three months ended ~~December~~March 31, ~~2021~~2022, interest expense totaled $~~192,643 and included $191,400 of liquidated damages and penalties due to our default on the Firstfire Notes~~690. During the ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022, interest expense totaled $279,~~007~~697 and included ~~the~~ $191,400 ~~described~~of ~~above~~liquidated damages and penalties due to our default on the Firstfire Notes and $79,200 of interest expense related to the Firstfire Notes.

Liquidity and Capital Resources

As of ~~December~~March 31, ~~2021~~2022, our cash totaled $6127,~~693~~416, compared to current liabilities of $1,~~936~~895,~~602~~932. From inception to ~~December~~March 31, ~~2021~~2022, we have incurred an ~~accumulated~~ accumulated deficit of $1718,~~833~~767,~~783~~796. This loss has been incurred through a combination of professional fees, R&D, SG&A and non-cash stock related costs of $1213,~~474~~203,~~169~~119 to support our plans to develop our business. During the three and ~~six~~nine months ended March ~~December~~ 31, ~~2021~~2022, the Company had negligible revenues and used cash in operations of $1,~~827~~940,~~644~~791. The Company has incurred losses since inception and may not be able to generate sufficient net revenue from its business in the future to achieve or sustain profitability. The Company currently has insufficient funds to operate over the next twelve months. To finance our operations, we have entered into a Common Stock Purchase Agreement with EMC2 Capital LLC, which provided us with $~~325~~76,~~000~~871 and $1,~~400~~476,~~000~~872 during the three and ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022, respectively.. Additionally, we entered into a Securities Purchase Agreement and related 12% senior secured convertible promissory note on June 18, 2021 and August 27, 2021, under which the Company received net proceeds of $224,500 on July 8, 2021 and $313,700 on September 2, 2021. We are currently pursuing additional funds through equity or debt financing or a combination thereof. However, aside from the EMC2 SPA, the Company has no commitments to obtain any such financing, and there can be no assurance that financing will be available in amounts or on terms acceptable to the Company, if at all.

Summary of Cash Flows

Presented below is a table that summarizes the cash provided or used in our activities and the amount of the respective increases or decreases in cash provided by (used in) those activities between the fiscal periods:

	Six Months Ended December 30,						Increase / (Decrease)
	Nine Months Ended March 31,						Increase / (Decrease)
	2021			2020
	2022			2021
Operating activities	$	(1,~~827~~940,~~644~~791	)	$	(~~424~~496,~~089~~861	)	$	1,~~403~~443,~~555~~930
Investing activities		—			(3,505	)		(3,505	)
Financing activities		1,~~814~~893,~~635~~505			~~419~~486,~~922~~698			(1,~~394~~406,~~713~~807	)
Net increase (decrease) in cash	$	(1347,~~009~~286	)	$	(713,~~672~~668	)	$	533,~~337~~618

Operating Activities

Net cash used in operating activities increased $1,~~403~~443,~~555~~930 primarily due to increases in R&D, professional fees, personnel and other SG&A costs.

Investing Activities

Net cash used in investing activities decreased $3,505 due to the purchase of computer equipment during ~~six~~the nine months ended ~~December~~March 31, ~~2020~~2021 compared to no investing related cash flows during the ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022.

Financing Activities

During the ~~six~~nine months ended ~~December~~March 31, ~~2021~~2022, the Company received $1,~~400~~479,000 upon the sale of 57,~~520~~856,~~771~~514 shares of common stock, and $538,200 from the sale of convertible promissory notes offset by debt payments totaling $123,565.

Other Contractual Obligations

None.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon our Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates based on its historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Due to the level of activity and lack of complex transactions, we believe there are currently no critical accounting policies and estimates that affect the preparation of our financial statements.

Recently Issued Accounting Pronouncements

See Note 2 to our consolidated financial statements, “Interim Statement Presentation - Accounting Pronouncements” under Item 1 in this Quarterly Report on Form 10-Q.

Related Party Transactions

For a discussion of our Related Party Transactions, see “Note 4 - Transactions With Related Persons” to our Financial Statements included under Item 1 in this Quarterly Report on Form 10-Q.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of ~~December~~March 31, ~~2021~~2022, that our disclosure controls and procedures were effective such that the information required to be disclosed in our SEC filings is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we are involved in litigation and other proceedings. See Note 7 to our unaudited consolidated financial statements for information on certain legal proceedings, which is incorporated by reference herein.

Item 1A. Risk Factors

COVID-19 Pandemic Impact and Risk

Smaller reporting companies are not required to provide the information required by this Item 1A.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended ~~December~~March 31, 2021, the Company issued 21) 12,~~750~~500,000 shares in exchange for services valued at $~~690~~688,~~350~~000; 2) 2,666,666 shares upon the conversion of $80,000 of convertible note principal; and 3) 2,000,000 shares upon the exercise of a warrant.

All proceeds from sales of unregistered securities, if any, are used for general corporate purposes.

Item 6. Exhibits

Exhibit No	Description of Exhibit
2.1	Notice of Entry of Order, Eight Judicial District Court, Clark County, Nevada, Case No.: A-19-787038-P (Incorporated by reference to the Form 10 filed on December 19, 2019)
3.1	Articles of Incorporation (Incorporated by reference to Form S-1 filed on January 28, 2014)
3.2	By-Laws (Incorporated by reference to Form S-1 filed on January 28, 2014)
3.3	Certificate of Change dated May 9, 2019 (Incorporated by reference to Form 10 filed on December 19, 2019)
3.4	Certificate of Amendment dated May 9, 2019 (Incorporated by reference to Form 10 filed on December 19, 2019)
3.5	Certificate of Change dated August 30, 2019 (Incorporated by reference to Form 10 filed on December 19, 2019)
4.1	Stock Purchase and Sale Agreement between the Company and Lionsgate Funding Group, LLC dated May 23, 2019 (Incorporated by reference to Form 10 filed on December 19, 2019)
4.2	Media and Marketing Services Agreement between Global WholeHealth Partners Corp and Empire Associates, Inc. dated August 18, 2020 (Incorporated by reference to the Form 8-K filed on August 21, 2020)
4.3	Form of Common Stock Purchase Agreement between Global WholeHealth Partners Corp and EMC2 Capital, LLC dated July 22, 2020 (Incorporated by reference to the Form 8-K filed on July 23, 2020)
4.4	Form of Common Stock Purchase Warrant between Global WholeHealth Partners Corp and EMC2 Capital, LLC dated July 22, 2020 (Incorporated by reference to the Form 8-K filed on July 23, 2020)
4.5	Registration Rights Agreement between Global WholeHealth Partners Corp and EMC2 Capital, LLC dated July 22, 2020 (Incorporated by reference to the Form 8-K filed on July 23, 2020)
4.6	Form of Stock Purchase Agreement between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated July 13, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
4.7	Form of Convertible Promissory Note between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated July 13, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
4.8	Form of Stock Purchase Agreement between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated August 3, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
4.9	Form of Convertible Promissory Note between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated August 3, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
4.10	Form of Stock Purchase Agreement between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated April 26, 2021 (Incorporated by reference to Form 10-Q filed on May 24, 2021)
4.11	Form of Common Stock Purchase Warrant between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated April 26, 2021 (Incorporated by reference to Form 10-Q filed on May 24, 2021)
4.12	Form of Securities Purchase Agreement between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated June 18, 2021. (Incorporated by reference to Form 10-K filed on September 27, 2021).
4.13	Form of Senior Secured Convertible Promissory Note between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated June 18, 2021. (Incorporated by reference to Form 10-K filed on September 27, 2021).
4.14	Form of Security Agreement between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated June 18, 2021. (Incorporated by reference to Form 10-K filed on September 27, 2021).

Exhibit No	Description of Exhibit
4.15	Form of Common Stock Purchase Warrant issued to by Global WholeHealth Partners Corp to Firstfire Global Opportunities Fund, LLC dated June 18, 2021. (Incorporated by reference to Form 10-K filed on September 27, 2021).
4.16	Form of Securities Purchase Agreement between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated August 27, 2021. (Incorporated by reference to Form 10-Q filed on November 5, 2021)
4.17	Form of Senior Secured Convertible Promissory Note between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated August 27, 2021. (Incorporated by reference to Form 10-Q filed on November 5, 2021)
4.18	Form of Common Stock Purchase Warrant issued to by Global WholeHealth Partners Corp to Firstfire Global Opportunities Fund, LLC dated August 27, 2021. (Incorporated by reference to Form 10-Q filed on November 5, 2021)
4.19	Form of Registration Rights Agreement between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated August 27, 2021. (Incorporated by reference to Form 10-Q filed on November 5, 2021)
10.1	Distribution Agreement and Letter of Exclusivity (Incorporated by reference to Form 10 filed on March 20, 2020)
10.2	Form of Promissory Note between LionsGate Funding Group LLC and Global WholeHealth Partners Corp. dated March 29, 2020 (Incorporated by reference to the Form 10-Q filed on May 7, 2020)
10.3	Form of convertible promissory Note dated April 18, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
10.4	Licensing Agreement with Charles Strongo dated January 12, 2021 (Incorporated by reference to the Form 8-K filed on January 21, 2021)
10.5	Loan Agreement and Promissory Note between LionsGate Funding Group LLC and Global WholeHealth Partners Corp. dated January 27, 2021 (Incorporated by reference to the Form 10-Q filed February 16, 2021)
10.6	License Agreement with Charles Strongo dated March 21, 2021 (Incorporated by reference to Form 10-Q filed on May 24, 2021)
10.7	Mutual Sales and Marketing Agreement dated April 12, 2021 (Incorporated by reference to the Form 8-K filed on April 19, 2021)
10.8	Form of Promissory Note between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated April 26, 2021 (Incorporated by reference to Form 10-Q filed on May 24, 2021)
10.9	Standard Multi-Tenant Office Lease-Net dated September 14, 2021 (Incorporated by reference to Form 10-Q filed on November 5, 2021)
10.09	Standard Multi-Tenant Office Lease-Net dated September 14, 2021 (Incorporated by reference to Form 10-Q filed on November 5, 2021)
10.10	Memorandum of Understanding dated September 15, 2021 between Global WholeHealth Partners, Avant Gen, Inc. and Pan Probe Biotech (Incorporated by reference to Form 8-K filed on September 21, 2021)
31.1	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.INS	XBRL Instance Document – the instance document does not appear in the Interactive Data Files as its XBRL tags are embedded within the Inline XBRL document
101.SCH	XBRL Taxonomy Extension - Schema Document
101.CAL	XBRL Taxonomy Extension - Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension - Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension - Label Linkbase Document
101.PRE	XBRL Taxonomy Extension - Presentation Linkbase Document
104	Cover page formatted as Inline XBRL and contained in Exhibit 101

*Filed herewith

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Global WholeHealth Partners Corp.

By:	/s/ Charles Strongo Charles Strongo Chief Executive Officer, Chief Financial Officer and Director (Principal Executive Officer and Principal Financial Officer)
Date:	February 3, 2022

By: /S/ Rene Alvarez

Rene Alvarez

Chief Executive Officer, Chief Financial Officer and Director

(Principal Executive Officer and Principal Financial Officer)

Date: July 20, 2022

Filing Compare · Global Wholehealth Partners Corp